Abstract
BCOR-CCNB3 fusion sarcoma is a recently described undifferentiated sarcoma with a novel recurrent inversion of 2 nearby genes BCOR and CCNB3. It typically affects bone and soft tissues of the pelvis, extremity, and paraspinal region and pursues variable clinical course. Primary renal BCOR-CCNB3 fusion sarcoma is very rare, and only a small number of cases have been documented. Accurate diagnosis is often challenging, and there is not any agreement for the treatment of this entity due to its rarity. We report findings of primary renal BCOR-CCNB3 fusion sarcoma in a 16-year-old boy with a brief review of the literature.
References
1.
Pierron
G
, Tirode
F
, Lucchesi
C
, Reynaud
S
, Ballet
S
, Cohen-Gogo
S
, A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion
. Nat Genet
. 2012
;44
(4
):461
–6
. .2.
Kao
YC
, Owosho
AA
, Sung
YS
, Zhang
L
, Fujisawa
Y
, Lee
JC
, BCOR-CCNB3 fusion positive sarcomas: a clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas
. Am J Surg Pathol
. 2018
;42
(5
):604
–15
. .3.
Argani
P
, Kao
YC
, Zhang
L
, Bacchi
C
, Matoso
A
, Alaggio
R
, Primary renal sarcomas with BCOR-CCNB3 gene fusion: a report of 2 cases showing histologic overlap with clear cell sarcoma of kidney, suggesting further link between BCOR-related sarcomas of the kidney and soft tissues
. Am J Surg Pathol
. 2017
;41
(12
):1702
–12
. .4.
Wong
MK
, Ng
CCY
, Kuick
CH
, Aw
SJ
, Rajasegaran
V
, Lim
JQ
, Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion
. Histopathology
. 2018
;72
(2
):320
–9
. .5.
Yoshida
A
, Arai
Y
, Hama
N
, Chikuta
H
, Bando
Y
, Nakano
S
, Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults
. Histopathology
. 2020
;76
(4
):509
–20
. .6.
Han
H
, Bertrand
KC
, Patel
KR
, Fisher
KE
, Roy
A
, Muscal
JA
, BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney
. Pediatr Blood Cancer
. 2020
;67
(4
):e28151
. .7.
Setoodeh
S
, Palsgrove
DN
, Park
JY
, Pedrosa
I
, Kapur
P
, Jia
L
. Primary renal sarcoma with BCOR-CCNB3 gene fusion in an 18-year-old male: a rare lesion with a diagnostic quandary
. Int J Surg Pathol
. 2021
;29
(2
):194
–7
. .8.
Antonescu
CR
, Plus
F
, Tirode
F
. Sarcoma with BCOR genetic alterations
. WHO classification of tumours editorial board. Soft tissue and bone tumours
. 5th ed. Lyon
: International Agency for Research on Cancer
; 2020
. p. 333
–5
.9.
Kao
YC
, Sung
YS
, Zhang
L
, Jungbluth
AA
, Huang
SC
, Argani
P
, BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities
. Am J Surg Pathol
. 2016
;40
(12
):1670
–8
. .10.
Cohen-Gogo
S
, Cellier
C
, Coindre
JM
, Mosseri
V
, Pierron
G
, Guillemet
C
, Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Société Française des Cancers de L’Enfant
. Pediatr Blood Cancer
. 2014
;61
(12
):2191
–8
.11.
Kyriazoglou
A
, Bagos
P
. Meta-analysis of BCOR rearranged sarcomas: challenging the therapeutic approach
. Acta Oncol
. 2021 Jun
;60
(6
):721
–6
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
